Ribociclib induced acute kidney injury: A case report

2021 ◽  
pp. 107815522110072
Author(s):  
Ilkay Gulturk ◽  
Mesut Yilmaz ◽  
Aykut Ozmen ◽  
Seher Yıldız Tacar ◽  
Gülçin Sahingoz Erdal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Acute Kidney Injury ◽  
Case Report ◽  
Dose Reduction ◽  
Metastatic Breast ◽  
Kidney Injury ◽  
Treatment Discontinuation ◽  
Close Monitoring ◽  
First Case ◽  
Grade 3

Introduction Among females, breast cancer is the most common type of cancer. Hormon receptor positive (HR+) subtype constitutes 75% of the diagnosed breast cancers. Combination of the cyclin D-cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and endocrine therapy significantly improves overall survival and progression-free survival. Ribociclib is an oral CDK 4/6 inhibitor and some adverse effects are identified. According to MONALEESA 2-3-7 studies, no adverse effect (AE) were reported due to grade 3 or 4 acute kidney injury (AKI) that caused treatment discontinuation. Case report We report a ribociclib-induced grade 3 AKI in an elderly woman who was treated for metastatic breast cancer. During first cycle of therapy, she was admitted to the oncology clinic with diagnosis of AKI. Management and outcome: Ribociclib treatment was discontinued and secondary causes of AKI were excluded. During the follow-up, kidney function values returned to the normal range spontaneously. Ribociclib treatment was re-initiated by reducing the dose (400 mg daily). Despite dose reduction; grade 3 AKI recurred when ribociclib was re-initiated and the drug was permanently discontinued. Discussion According to MONALEESA 2-3-7 studies; no AE were reported due to grade 3 or 4 AKI. Despite these studies, the FDA reported that 20% of patients with ribociclib + letrozole combination therapy may have any stage elevation of creatinine. Ribociclib induced creatinine elevations are generally mild (grade 1–2) and can be managed by dose reduction or close monitoring of creatinine levels. We report the first case of grade 3 AKI that caused treatment discontinuation following administration of ribociclib.

scholarly journals The Use of Supra-Hemodiafiltration in Traumatic Rhabdomyolysis and Acute Kidney Injury: A Case Report

2021 ◽  
pp. 26-35
Author(s):  
Gabriele Donati ◽  
Maria Cappuccilli ◽  
Federica Di Filippo ◽  
Simone Nicoletti ◽  
Marco Ruggeri ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Case Report ◽  
Septic Patient ◽  
Medical Therapy ◽  
Kidney Injury ◽  
First Case ◽  
Successful Recovery

Oliguric acute kidney injury due to traumatic rhabdomyolysis can be potentially lethal if the proper medical therapy combined with extracorporeal detoxification is not performed. Different extracorporeal techniques are available to overcome this syndrome. Here, we report the first case of removal of myoglobin and successful recovery from acute kidney injury in an elderly septic patient using supra-hemodiafiltration with endogenous reinfusion technique (HFR-Supra) combined with the medical therapy.

scholarly journals Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report

2020 ◽  
Vol 13 (1) ◽  
pp. 304-308 ◽  
Author(s):  
Alyssa Schlotman ◽  
Adam Stater ◽  
Kyle Schuler ◽  
Judd Heideman ◽  
Vandana Abramson
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Metastatic Breast ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Hepatotoxic Effect ◽  
Er Positive ◽  
Grade 3 ◽  
Experienced Grade

A 49-year-old woman with ER-positive/PR-negative/HER2-negative metastatic breast cancer experienced Grade 3 hepatotoxicity following initiation of a clinical trial of fulvestrant, palbociclib, and erdafitinib. Fulvestrant was determined to be the drug most likely responsible for this hepatotoxic effect. This case report details the timing and nature of this drug-induced liver injury, adding support to an area that has yet to be described adequately in the existing literature.

scholarly journals Rivaroxaban-related acute kidney injury in a patient with IgA vasculitis

2019 ◽  
Vol 12 (1) ◽  
pp. e227756 ◽  
Author(s):  
Yoshihiko Fujino ◽  
Chisato Takahashi ◽  
Kensuke Mitsumoto ◽  
Takashi Uzu
Keyword(s):  
Atrial Fibrillation ◽  
Acute Kidney Injury ◽  
Renal Function ◽  
Systemic Vasculitis ◽  
Kidney Injury ◽  
Close Monitoring ◽  
Iga Vasculitis ◽  
Direct Oral Anticoagulant ◽  
Macroscopic Haematuria ◽  
First Case

Anticoagulants have recently been recognised as a cause of acute kidney injury (AKI). We describe the case of a 75-year-old man with IgA vasculitis and atrial fibrillation treated with rivaroxaban, who presented with macroscopic haematuria and an acute decline in renal function. Two months before referral, he noted palpable purpuric lesions and was diagnosed with IgA vasculitis based on skin biopsy findings; the skin lesion disappeared following treatment with a steroid external preparation. Renal biopsy revealed glomerular haemorrhage and red blood cell casts. Although rivaroxaban was withdrawn, his kidney function worsened and he was started on haemodialysis. His renal function did not recover. To the best of our knowledge, this is the first case of direct oral anticoagulant (DOAC)-related AKI in systemic vasculitis. During DOAC therapy, close monitoring of a patient’s urinalysis results and their renal function may be required for patients with systemic vasculitis to avoid AKI.

scholarly journals Everolimus in acute kidney injury in a patient with breast cancer: a case report

2014 ◽  
Vol 8 (1) ◽  
Author(s):  
Francesca Donders ◽  
Dirk Kuypers ◽  
Pascal Wolter ◽  
Patrick Neven
Keyword(s):  
Breast Cancer ◽  
Acute Kidney Injury ◽  
Case Report ◽  
Kidney Injury

scholarly journals Case Report of a Rare Incidence of IgH Amplification Leading to Acute Kidney Injury in a Multiple Myeloma Patient

2021 ◽  
pp. 274-278
Author(s):  
Sowmya Thanikachalam ◽  
Vijay Kumar Srinivasalu ◽  
K.S. Nataraj ◽  
Sharat Damodar ◽  
Manjula Das
Keyword(s):  
Multiple Myeloma ◽  
Acute Kidney Injury ◽  
Case Report ◽  
Heavy Chain ◽  
Kidney Injury ◽  
Bone Marrow Aspiration ◽  
Structural Abnormality ◽  
Cell Transplant ◽  
Multiple Myeloma Patient ◽  
First Case

We present a case report of a 62-year-old male, treated for kappa light chain multiple myeloma with chemotherapy followed by autologous stem cell transplant (ASCT) in 2014. He has been in complete remission for 4 years. In 2018, he was evaluated for hypercreatinemia and acute kidney injury(AKI) with a suspicion of disease relapse; he underwent evaluation with bone marrow aspiration cytology which showed no evidence of relapse. However, careful cytogenetic analyses showed IgH amplification (14q32) which probably was the cause for AKI in the absence of any structural abnormality in the kidney. Heavy chain deposition leads to AKI in multiple myeloma, and its association with IgH amplification leading to AKI is reported here. Though heavy chain deposition leading to AKI is common, IgH amplification at chromosome level is the first case observed.

Coagulopthy, acute kidney injury and death following Hypnale zara envenoming – The first case report from Sri Lanka

Toxicon ◽  
2011 ◽  
Vol 58 (8) ◽  
pp. 641-643 ◽  
Author(s):  
Kalana Maduwage ◽  
Keerthi Kularatne ◽  
Abdul Wazil ◽  
Indika Gawarammana
Keyword(s):  
Acute Kidney Injury ◽  
Case Report ◽  
Sri Lanka ◽  
Kidney Injury ◽  
First Case

scholarly journals Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant

2020 ◽  
Vol 38 (5) ◽  
pp. 388-394 ◽  
Author(s):  
Jennifer K. Litton ◽  
Marion E. Scoggins ◽  
Kenneth R. Hess ◽  
Beatriz E. Adrada ◽  
Rashmi K. Murthy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dose Reduction ◽  
Response Rate ◽  
Single Agent ◽  
Pathologic Complete Response ◽  
Metastatic Breast ◽  
Operable Breast Cancer ◽  
Pathologic Response ◽  
Pathogenic Variant ◽  
Grade 3

PURPOSE Talazoparib has demonstrated efficacy in patients with BRCA-positive metastatic breast cancer. This study evaluated the pathologic response of talazoparib alone for 6 months in patients with a known germline BRCA pathogenic variant (g BRCA-positive) and operable breast cancer. METHODS Eligibility included 1 cm or larger invasive tumor and g BRCA-positive disease. Human epidermal growth factor receptor 2–positive tumors were excluded. Twenty patients underwent a pretreatment biopsy, 6 months of once per day oral talazoparib (1 mg), followed by definitive surgery. Patients received adjuvant therapy at physician’s discretion. The primary end point was residual cancer burden (RCB). With 20 patients, the RCB-0 plus RCB-I response rate can be estimated with a 95% CI with half width less than 20%. RESULTS Twenty patients were enrolled from August 2016 to September 2017. Median age was 38 years (range, 23 to 58 years); 16 patients were g BRCA1 positive and 4 patients were g BRCA2 positive. Fifteen patients had triple-negative breast cancer (estrogen receptor/progesterone receptor < 10%), and five had hormone receptor-positive disease. Five patients had clinical stage I disease, 12 had stage II, and three had stage III, including one patient with inflammatory breast carcinoma and one with metaplastic chondrosarcomatous carcinoma. One patient chose to receive chemotherapy before surgery and was not included in RCB analyses. RCB-0 (pathologic complete response) rate was 53% and RCB-0/I was 63%. Eight patients (40%) had grade 3 anemia and required a transfusion, three patients had grade 3 neutropenia, and 1 patient had grade 4 thrombocytopenia. Common grade 1 or 2 toxicities were nausea, fatigue, neutropenia, alopecia, dizziness, and dyspnea. Toxicities were managed by dose reduction and transfusions. Nine patients required dose reduction. CONCLUSION Neoadjuvant single-agent oral talazoparib once per day for 6 months without chemotherapy produced substantial RCB-0 rate with manageable toxicity. The substantive pathologic response to single-agent talazoparib supports the larger, ongoing neoadjuvant trial (ClinicalTrials.gov identifier: NCT03499353 ).

scholarly journals Pneumocystis Pneumonia and Acute Kidney Injury Induced by Everolimus Treatment in a Patient with Metastatic Breast Cancer

2020 ◽  
Vol 13 (1) ◽  
pp. 170-175 ◽  
Author(s):  
Mayuko Nakamura ◽  
Ryoichi Matsunuma ◽  
Kei Yamaguchi ◽  
Ryosuke Hayami ◽  
Michiko Tsuneizumi
Keyword(s):  
Breast Cancer ◽  
Acute Kidney Injury ◽  
Adverse Event ◽  
Metastatic Breast Cancer ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Metastatic Breast ◽  
Kidney Injury ◽  
Pneumocystis Pneumonia ◽  
Er Positive

Everolimus, an inhibitor of the rapamycin pathway, is administered with the combination of an aromatase inhibitor for the treatment of metastatic estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancers. Interstitial lung disease is a well-known major adverse event associated with everolimus treatment, but it is often difficult to distinguish between interstitial lung disease and Pneumocystis pneumonia, a lung infection. Acute kidney injury is another adverse event that is associated with everolimus use. In this article, we report a case of Pneumocystis pneumonia without respiratory symptoms and acute kidney injury induced by everolimus treatment in a patient with ER-positive and HER2-negative metastatic breast cancer.

scholarly journals Everolimus-associated acute kidney injury in patients with metastatic breast cancer

2017 ◽  
Vol 27 (5) ◽  
pp. 406 ◽  
Author(s):  
NS Rao ◽  
A Chandra ◽  
KP Malhotra ◽  
M Rastogi ◽  
R Khurana
Keyword(s):  
Breast Cancer ◽  
Acute Kidney Injury ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Kidney Injury

St. John’s Wort (Hypericum perforatum)-Related Acute Kidney Injury

2021 ◽  
pp. 1-3
Author(s):  
Zelal Adibelli ◽  
Ilayda Karacay ◽  
Murat Demir ◽  
Cevdet Duran
Keyword(s):  
Acute Kidney Injury ◽  
Case Report ◽  
Sleep Disorder ◽  
Kidney Failure ◽  
Hypericum Perforatum ◽  
Kidney Injury ◽  
Acute Kidney Failure ◽  
Normal Kidney ◽  
Herbal Products ◽  
First Case

Some herbal products were reported to cause nephrotoxicity through different mechanisms. This case report defines an acute kidney injury (AKI) in a patient who used <i>Hypericum perforatum</i> tea as a sleep disorder remedy. The patient developed AKI after ingestion of tea prepared from <i>Hypericum perforatum</i> and underwent hemodialysis because of acute kidney failure. After 1 week, the kidney recovered, and she was discharged with normal kidney function. This is the first case reported having acute kidney failure caused by ingestion of <i>Hypericum perforatum</i>.

Sign in / Sign up

Export Citation Format

Share Document